Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00352963
Status:
COMPLETED
Last Update Posted:
2020-01-06
First Post:
2006-07-14
Brief Title:
Immunogenicity Safety Study of CombinedSeparate Vaccines Against Common Diseases in Infants 246 Months of Age
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Study to Assess Immunogenicity and Reactogenicity of Three Doses of GSK Bios Combined Hib-MenC Vaccine Co-admind With GSK Bios DTPa-HBV-IPV Vaccine and of Two Doses of Baxters Meningococcal C Conjugate Vaccine Co-admind With GSK Bios DTPa-HBV-IPVHib Vaccine
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa IPV hepatitis B Hib and Men C vaccines during the first year of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None